Print pageEmail pageRSS Feeds

Corporate Profile

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.

NASDAQ : ARIA (Common Stock)
$6.47 - 0.05
Stock chart for: ARIA.O.  Currently trading at $6.47 with a 52 week high of $10.07 and a 52 week low of $5.55.
11/27/15 1:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
You are now leaving this website. If you would like to continue, click Continue.